Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q2 2022 call → NOWe need to determine if management repeatedly redirects attention away from the conventional yardstick (likely MA distribution, EBITDA, revenue) toward a different part of the business that is already earning today, and indicates that the record has not caught up. Let's analyze the transcript. The call is about Q2 2022 results, which were disappointing. Management discusses challenges in the senior Medicare Advantage distribution business, including close rates, persistency, cohort tail adjustments, etc. They also discuss a strategic review and changes. Key points: - They acknowledge disappointing results, with revenue down, EBITDA negative. - They discuss headwinds: labor market, CMS marketing review, plan parity, lower close rates, higher lapse rates, cohort tail adjustment. - They talk about resetting growth philosophy, reducing operating leverage, etc. - They highlight Population Health initiatives, particularly SelectRx, as a bright spot. They mention over 40,000 gross enrollments, 10,000 active paying members, and progress. Now, the question: Does management repeatedly redirect attention away from the conventional yardstick (likely the MA distribution business, revenue, EBITDA) toward a different part (Population Health, SelectRx) that is already earning today, and indicate that the record has not caught up? Let's see if they set aside the conventional yardstick. They do discuss the challenges in the core business, but they also talk about strategic shift. They mention that the company's value extends beyond MA, and they are focusing on Population Health. However, do they explicitly say that the conventional yardstick (e.g., MA policy production, EBITDA) is no longer the right thing to watch? They do say that they are resetting growth philosophy, but they still discuss MA as a core part. They also say that the results are unacceptable and they are making changes. They highlight SelectRx as a bright spot, with concrete numbers: 40,000 enrollments, 10,000 active members, and they are confident in reaching 25,000 by year-end. This is already earning, with real customers. Do they indicate that the record has not caught up? They say that the results are disappointing, and they are transitioning. They mention that the MA business is being reset, and that Population Health is a growing contributor.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.